Core Laboratories Inc DE
For the period ended Dec 31, 2023. Filed Feb 15, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 15, 2024
CLB$8.95-0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibit and Financial Statement Schedules
ITEM 15. EXHIBITS AND FINA NCIAL STATEMENT SCHEDULES
(a)
Financial Statements
- The following reports, financial statements and schedules are filed herewith on the pages indicated:
| Page | |
| Reports of Independent Registered Public Accounting Firm-KPMG LLP | F-1 |
|---|---|
| Consolidated Balance Sheets as of December 31, 2023 and 2022 | F-4 |
| Consolidated Statements of Operations for the Years Ended December 31, 2023, 2022 and 2021 | F-5 |
| Consolidated Statements of Comprehensive Income (Loss) for the Years Ended December 31, 2023, 2022 and 2021 | F-6 |
| Consolidated Statements of Changes in Equity for the Years Ended December 31, 2023, 2022 and 2021 | F-7 |
| Consolidated Statements of Cash Flows for the Years Ended December 31, 2023, 2022 and 2021 | F-9 |
| Notes to the Consolidated Financial Statements | F-11 |
- Financial Statement Schedule
Schedule II - Valuation and Qualifying Account
(b)
Exhibits
The exhibits listed in the accompanying “Index to Exhibits” are incorporated by reference to the filing indicated or are filed herewith.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.